



Published in final edited form as:

Clin Pharmacol Ther. 2019 July ; 106(1): 94–102. doi:10.1002/cpt.1409.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for *CYP2D6* Genotype and Atomoxetine Therapy

Jacob T. Brown¹, Jeffrey R. Bishop², Katrin Sangkuhl³, Erika L. Nurmi⁴, Daniel J. Mueller⁵, Jean C. Dinh⁶, Andrea Gaedigk^{6,7}, Teri E. Klein³, Kelly E. Caudle⁸, James T. McCracken⁴, Jose de Leon⁹, and J. Steven Leeder^{6,7}

¹Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota College of Pharmacy, Duluth, MN, USA

²Department of Experimental and Clinical Pharmacology, College of Pharmacy, and Department of Psychiatry, Medical School, University of Minnesota, Minneapolis, Minnesota, USA

³Department of Biomedical Data Science, Stanford University, Stanford, California, USA

⁴Department of Psychiatry and Biobehavioral Sciences, Division of Child and Adolescent Psychiatry, University of California, Los Angeles, Los Angeles, CA, USA

⁵Department of Psychiatry, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada

⁶Department of Pediatrics, Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, USA

⁷School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA

⁸Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA

Corresponding Author: J. Steven Leeder, Pharm.D., Ph.D., Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO 64108, Phone: (816) 302-3001, sleeder@cmh.edu.

DISCLAIMER

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making, as well as to identify questions for further research. New evidence may have emerged since the time a guideline was submitted for publication. Guidelines are limited in scope and are not applicable to interventions or diseases not specifically identified. Guidelines do not account for all individual variation among patients and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health care provider to determine the best course of treatment for the patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be solely made by the clinician and the patient. CPIC assumes no responsibility for any injury to persons or damage to property related to any use of CPIC's guidelines, or for any errors or omissions.

CPIC is a registered service mark of the U.S. Department of Health & Human Services (HHS).

CONFLICT OF INTEREST

THE AUTHORS DECLARED NO COMPETING INTERESTS FOR THIS WORK.

Supplementary Material

(2018-0834CR_Supplemental_Material.pdf)

Supplement to: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for *CYP2D6* and Atomoxetine Therapy

(2018-0834CR_Implementation_Tables.zip)

Implementation Tables

⁹University of Kentucky Mental Health Research Center, Eastern State Hospital, Lexington, KY, USA

Abstract

Atomoxetine is a non-stimulant medication used to treat attention-deficit/hyperactivity disorder. *CYP2D6* polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on *CYP2D6* genotype (updates at www.cpicpgx.org).

Keywords

atomoxetine; ADHD; CYP2D6; CPIC; pharmacogenetics; pharmacogenomics

INTRODUCTION

The purpose of this guideline is to provide information to allow the interpretation of clinical *CYP2D6* genotype tests so that the results can be used to guide the use of atomoxetine. Detailed guidelines for prescribing of atomoxetine as well as analyses of cost effectiveness are beyond the scope of this document. The Clinical Pharmacogenetic Implementation Consortium (CPIC®) guidelines are periodically updated at <https://cpicpgx.org/guidelines/> and <http://www.pharmgkb.org>.

FOCUSED LITERATURE REVIEW

A systematic literature review focused on *CYP2D6* genotype and atomoxetine use was conducted (details in Supplement).

GENE: CYP2D6

CYP2D6 is highly polymorphic with over 100 known allelic variants and subvariants identified (www.PharmVar.org; *CYP2D6* Allele Definition Table (1, 2)). *CYP2D6* alleles have been extensively studied in multiple geographically, racially, and ethnically diverse groups and significant differences in allele frequencies have been observed (*CYP2D6* Allele Frequency Table (1, 2)). The most commonly reported alleles are categorized into functional groups as follows: normal function (e.g., *CYP2D6**1, *2 and *35), decreased function (e.g., *CYP2D6**9, *10, *17, *29 and *41), and no function (e.g., *CYP2D6**3-*6) (3, 4). Because *CYP2D6* is subject to deletions and gene duplications or multiplications, many clinical laboratories also report copy number variations. *CYP2D6**5 represents a gene deletion (no function allele) whereas gene duplications and multiplications are denoted by “xN” (e.g., *CYP2D6**1xN with xN representing the number of *CYP2D6* gene copies). Alleles carrying two or more normal function gene copies are categorized as alleles with increased function.

The combination of alleles is used to determine a patient’s diplotype. Each functional group is assigned an activity value ranging from 0 to 1 (e.g., 0 for no, 0.5 for decreased and 1.0 for normal function) (4). If an allele contains multiple copies of a functional gene, the value is

multiplied by the number of copies present. Thus, the *CYP2D6* activity score is the sum of the values assigned to each allele, which typically range from 0 to 3.0 but may exceed 3.0 in rare cases (4).

The *CYP2D6* activity score can be translated into a standardized phenotype classification system (*CYP2D6* Allele Definition Table (1, 2)): patients with an activity score of 0 are poor metabolizers (PMs), those with a score of 0.5 are considered intermediate metabolizers (IMs), those with a score of 1.0–2.0 represent normal metabolizers (NMs) and patients with a score >2 are classified as ultrarapid metabolizers (UMs). However, diplotypes with an activity score of 1.0 give rise to less activity towards certain drugs including tamoxifen and atomoxetine compared to those with an AS of 1.5 or 2.0; therefore, patients with an activity score of 1.0 may be classified as IMs by some reference laboratories. Thus, for this guideline, an activity score of 1.0 is classified as a *CYP2D6* NM or IM (Table 1). This is in contrast to the classification used in some previous guidelines (5, 6) but similar to the recently published guideline on *CYP2D6* and tamoxifen (7). Note that genotypes with an activity score of 1 are classified as NMs in the *CYP2D6* Genotype to Phenotype Table (1) and CPIC will update the CPIC website and this table if needed. Efforts to standardize *CYP2D6* genotype to phenotype translation system are ongoing. Currently, a *CYP2D6* Genotype-to-Phenotype Working Group is also reviewing the classification of the decreased function *CYP2D6*10* allele (discussions regarding the accuracy of *CYP2D6*10* classification using a value of 0.5 for activity score calculation have been ongoing for years (7)). This allele appears to convey a reduction in activity across many substrates, which led to a special recommendation for *CYP2D6*10*-containing diplotypes for tamoxifen and for atomoxetine (Table 2).

Of importance, reference laboratories providing clinical *CYP2D6* genotyping may use varying methods to assign phenotypes. Therefore, it is advisable to note a patient's *CYP2D6* diplotype and to calculate its activity score before making therapeutic decisions about atomoxetine therapy. See the *CYP2D6* Diplotype to Phenotype Table for a comprehensive translation of diplotype to phenotype (1, 2).

Genetic Test Interpretation

Clinical laboratories rarely sequence through the *CYP2D6* gene or interrogate every known variant position. Instead, they typically test for variants that are used to determine common allele haplotypes using the star-allele (*) nomenclature system. Allele definitions are maintained by the Pharmacogene Variation Consortium (www.PharmVar.org). The *CYP2D6* Allele Definition Table and *CYP2D6* Allele Functionality Table and tables found on the PharmGKB website contain a list of *CYP2D6* alleles (1, 2), the specific combination of variants that can be used to determine the allele, functional status, and frequency across major ethnic populations as reported in the literature.

Genetic test results are reported as diplotypes, or the combination of the maternal and paternal alleles (e.g. *CYP2D6*1/*2*). Phenotypes are assigned based on the reported *CYP2D6* diplotype, as summarized in Table 1 and in the *CYP2D6* Dipl Table.

The limitations of genetic testing as described here include: (1) rare variants are often not detected; (2) known star alleles (*) which are not tested by a specific lab will not be reported, and instead, the patient will be reported as a *1, and 3) most tests are not designed to detect unknown or *de novo* variants. Supplemental Material (Genetic Test Interpretation Section) contains additional information regarding *CYP2D6* genetic test interpretation and phenotype assignment.

Available Genetic Test Options

See Supplemental Material and the Genetic Testing Registry (GTR®) (www.ncbi.nlm.nih.gov/gtr/) for more information on commercially available clinical testing options.

Incidental findings

Currently, there are no diseases or conditions which have been consistently linked to variation in the *CYP2D6* gene independent of drug metabolism and response.

Other considerations

CYP2D6 is the primary enzyme responsible for the metabolism of many other commonly-used medications. It is important to note that variation in CYP2D6 may have implications for other therapies that are beyond the scope of this guideline. CPIC guidelines exist for other drugs metabolized by CYP2D6 (3, 6–9).

DRUGS: ATOMOXETINE

Background

Based on a parent-reported survey in 2016, an estimated 6.1 million children (9 %) between the ages of 2–17 years received a diagnosis of attention-deficit/hyperactivity disorder (ADHD) (10). Although not a first-line agent for the treatment of ADHD, atomoxetine was the first non-stimulant medication approved in the United States to treat ADHD in 2002. Originally developed in the 1980s to treat adult depression, but only approved for the treatment of ADHD, atomoxetine is a selective norepinephrine reuptake inhibitor (11). A surge in atomoxetine prescriptions occurred following its approval, peaking in 2004 when it was the third most commonly prescribed medication for ADHD after methylphenidate and amphetamine/dextroamphetamine; however, following 2004 prescriptions gradually decreased to around 2 million per year in 2010 (12). Unlike stimulants, atomoxetine has a delayed onset to clinical effect and typically takes 2–4 weeks for full impact on symptoms to be observed (13).

Atomoxetine is an active parent compound and is metabolized by CYP2D6 to an active metabolite, 4-OH-atomoxetine; however, this metabolite is rapidly glucuronidated to the inactive 4-OH-atomoxetine-*O*-glucuronide and the unconjugated metabolite circulates at concentrations approximately 100-fold lower than the parent compound (14, 15). To a lesser extent, atomoxetine is also metabolized by CYP2C19 to *N*-desmethylatomoxetine, which is subsequently metabolized via CYP2D6 to *N*-desmethyl-4-hydroxyatomoxetine (Figure 1).

The recommended initial daily dose of atomoxetine is 0.5 mg/kg in children and adolescents up to 70 kg with a target and maximum dose of 1.2 mg/kg/day and 1.4 mg/kg/day, respectively. In children and adolescents over 70 kg and adults, the initial daily dose of atomoxetine is 40 mg/day, with a target and maximum daily dose of 80 mg/day and 100 mg/day, respectively (according to the product labeling). In patients taking a CYP2D6 inhibitor or those who are known to be CYP2D6 PMs, the product labeling currently recommends starting therapy at the usual daily dose and increasing to the recommended target doses if the drug is well tolerated and symptoms fail to improve after four weeks.

In registry clinical trials for the efficacy and safety of atomoxetine, separation from placebo was, on average, observed after 1–2 weeks of treatment (13). Incremental increases in response may occur for up to 24 weeks or longer. Pharmacokinetic studies highlight that doses producing atomoxetine peak concentrations greater than 200 ng/ml 1–4 hours after dosing may increase the likelihood of response (16). Common dose-related side effects from atomoxetine occurring more frequently in CYP2D6 PMs compared to non-PMs in children or adults include dry mouth, blurred vision, sleep disturbances, decreased weight or appetite, constipation, depression, tremor, feeling jittery, excoriation, dry eye or conjunctivitis, syncope, urinary retention, sexual dysfunction, hyperhidrosis, peripheral coldness, and elevated blood pressure (16).

Linking genetic variability to variability in drug-related phenotypes

Atomoxetine pharmacokinetics.—A strong association exists between *CYP2D6* genotype and atomoxetine pharmacokinetic variability (see Table S2). Atomoxetine is considered a CYP2D6 “sensitive substrate” by the U.S. Food and Drug Administration (FDA) for evaluating drug-drug interactions. As such, *CYP2D6* genetic variation has a profound effect on atomoxetine pharmacokinetics (17). The range of values observed for atomoxetine exposure, most often reported as either the area under the drug plasma concentration-time curve (AUC) or the maximum concentration (C_{max}), is substantial. Atomoxetine exposure (AUC) is, *on average*, 10-fold higher in CYP2D6 PMs compared to non-PMs (14–16, 18, 19). However, the comparison of group mean values obscures the full range of exposures that may be present in a population. For example, a *CYP2D6* genotype-stratified single-dose pharmacokinetic study (n=23 children) observed a 30-fold range in AUC when dosed using the FDA-recommended initial dose of 0.5 mg/kg. Decreasing atomoxetine exposure was associated with genotype, i.e. increasing CYP2D6 activity scores (15). It should be noted that in early *in vivo* drug development studies, the depth of genotyping only differentiated between CYP2D6 PMs and non-PMs. Subsequent studies that performed more comprehensive genotyping suggest that CYP2D6 IMs (e.g., a CYP2D6 activity score of 0.5) have pharmacokinetic profiles that differ from both PMs and NMs (15).

Ex vivo studies evaluating metabolic capacity in human liver microsomes that have been genotyped for *CYP2D6* provide evidence that increased exposure is due to reduced metabolic capacity in both IMs and PMs (11, 20, 21). The most studied decreased function *CYP2D6* allele in the context of atomoxetine is the *CYP2D6*10* variant. Individuals with two *CYP2D6*10* alleles had higher atomoxetine exposure (5-fold higher peak concentration) when compared to individuals with at least one normal function allele (22–

24). Individuals heterozygous for **10* and one fully functional *CYP2D6* allele had higher atomoxetine exposure compared to individuals carrying two fully functioning alleles.

Atomoxetine response/toxicity.—The likelihood of favorable treatment response and side effects are both reported to be higher in CYP2D6 PMs compared to non-PMs, which is likely due to increased exposure to parent drug in the PMs. The extent of improvement in ADHD symptoms, *i.e.* mean change in ADHD symptom rating scale scores, was greater in PMs compared to non-PMs, while CYP2D6 non-PMs were also more likely to discontinue atomoxetine therapy due to inefficacy as compared to CYP2D6 PMs (16). Current evidence is limited to comparisons between CYP2D6 PMs and non-PMs; thus, there is no evidence correlating efficacy and/or drug discontinuation with other CYP2D6 phenotype classes. Higher exposures to atomoxetine may also partially explain a greater percentage of side effects in CYP2D6 PMs, such as increases in heart rate and diastolic blood pressure, when compared to non-PMs (16, 19, 25). However, in a retrospective study that evaluated atomoxetine response in participants enrolled from six atomoxetine randomized controlled trials (n=618), beneficial response was noted in 47% of patients, 13% of patients were determined to have minimal response, and 40% had no response (26). These data suggest at least two distinct atomoxetine response groups within the observed population. Additionally, it can also be inferred that *CYP2D6* genotype alone does not account for the atomoxetine response distribution described in the above investigation, given that CYP2D6 PMs frequency is ~5–10% of the population (Frequency table (2)).

The most well studied pharmacokinetic parameter for atomoxetine relates plasma drug concentrations that approximate the C_{max} of the parent compound to reduction of ADHD symptoms (16). Given this evidence, the therapeutic recommendation for each CYP2D6 phenotype class also includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure (*i.e.* exposure check). These target reference values are from the Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology, and are meant to guide the clinician in the event that patient response to atomoxetine is inadequate (27). Included with these guidelines is a plasma concentration (henceforth described as an ‘exposure check’) performed post drug administration which is included to rule out inadequate systemic exposure as a cause of non-response in individuals with a CYP2D6 activity score of 1 or more. This CPIC guideline also includes a grading system to evaluate the strength of evidence between various *CYP2D6* genotype-predicted phenotypes and the corresponding therapeutic recommendation. Data from both *in vitro* and *in vivo* studies (Table S1), as well as consensus recommendations were used in formulating the guidance in Table 2.

Therapeutic Recommendations

Tables 2 and 3 summarize the therapeutic recommendations for atomoxetine based on CYP2D6 phenotype in children and adults, respectively. Although not routinely ordered, patients may benefit from a single time point atomoxetine exposure check to guide therapy. Exposure check concentrations between 200 – 1000 ng/mL are generally considered to be “therapeutic” (16, 28), however for individuals with comorbidities a higher exposure target may be warranted, as was done in a study evaluating children with both ADHD and

Author Manuscript

Oppositional Defiant Disorder (29). We propose that the plasma concentration exposure check be used with an individual's *CYP2D6* genotype to help clinicians guide dose selection and titration as discussed below. Based on pharmacokinetic knowledge that *CYP2D6* metabolism phenotypes influence atomoxetine peak concentration and half-life, Tables 2 and 3 propose that prescribers consider measuring peak concentrations 1 to 2 hours after dosing in known *CYP2D6* UMs, NMs and IMs with high activity (activity score 1.0 without a *CYP2D6*10* allele), 2 to 4 hours after dosing in *CYP2D6* IMs with low activity (activity score 0.5) and in individuals with AS of 1 when the *CYP2D6*10* allele is present, and 4 hours after dosing in PMs.

Author Manuscript

Very limited data exist for *CYP2D6* UMs taking atomoxetine, but it is unlikely these individuals would achieve adequate serum concentrations with standard atomoxetine dosing (30). As discussed above, *CYP2D6* non-PMs have a lower likelihood of treatment response as compared to *CYP2D6* PMs (16). Thus, for *CYP2D6* UMs and NMs, recommendations are to initiate standard atomoxetine dosing (see Table 2 and 3 for pediatric and adult dosing, respectively) and if no clinical response is observed after two weeks, consider obtaining a peak plasma concentration one to two hours after dose administration. If the peak concentration is less than 200 ng/ml, consider increasing the dose proportionally to approach 400 ng/ml (16). It is important to note that doses above 120 mg have not been extensively evaluated, although they may be necessary to achieve target concentrations in some patients. While *CYP2D6* NMs with activity scores of 1 (without the presence of the *CYP2D6*10* allele) have higher atomoxetine plasma concentrations compared to NMs with an AS of 2, the clinical significance of this difference is unclear. Thus, *CYP2D6* NMs with an AS of 1 (without the presence of the *CYP2D6*10* allele) should be treated similarly to *CYP2D6* NMs with AS of 2.

Author Manuscript

CYP2D6 PMs, IMs, and NMs with an AS of 1 in the presence of the *CYP2D6*10* allele have significantly decreased metabolism of atomoxetine, which may increase the risk of side effects (16, 19, 25). However, these individuals may also have greater improvement of ADHD symptoms and lower dose requirements as compared to non-PMs. Therefore, the recommendation for these phenotype groups are to initiate with a standard starting dose (see Table 2 and 3 for pediatric and adult dosing, respectively) and if there is an inadequate trajectory of symptom improvement after 2 weeks (in the absence of side effects), consider obtaining a plasma concentration two-four hours after dosing. If response is inadequate and side effects are not present, consider adjusting the dose proportionally to approach 400 ng/ml.

Recommendations for Incidental Findings

Not applicable

Other considerations

Author Manuscript

In addition to *CYP2D6*, variation in atomoxetine response has also been examined with its pharmacodynamic target, the norepinephrine transporter, *SLC6A2*. Ramoz *et al.* describes significant associations between 20 SNPs within *SLC6A2* and responders as compared to

non-responders of atomoxetine (31). If other studies replicated this finding, future guidelines may consider incorporating this result in its recommendations.

Individuals taking atomoxetine along with a strong CYP2D6 inhibitor (e.g. bupropion, fluoxetine, paroxetine) may experience higher than expected concentrations based on their *CYP2D6* genotype through a process known as phenoconversion. This has been described for paroxetine and fluoxetine in non-PM metabolizers taking atomoxetine (32–34). For the duration of the phenoconversion (for fluoxetine it may last up to 2–3 months after fluoxetine discontinuation in average patients and longer in some individuals (35)) the individual phenotypically resembles a CYP2D6 PM regardless of genotype.

Implementation resources for this guideline.—The guideline supplement contains resources that can be used within electronic health records (EHRs) to assist clinicians in applying genetic information to patient care for the purpose of drug therapy optimization (see Resources to incorporate pharmacogenetics into an electronic health record with clinical decision support section in the supplement). Clinical implementation resources include cross-references for drug and gene names to widely-used terminologies and standardized nomenclature systems, workflow diagrams, a table that translates genotype test results into a predicted phenotype with genetic test interpretation, and example text for documentation in the EHR and point-of-care alerts.

POTENTIAL BENEFITS AND RISKS FOR THE PATIENT

The potential benefit of using an individual's *CYP2D6* genotype to guide atomoxetine dosing is that clinicians can be alerted to individuals who are more likely to fail treatment at standard dosing (e.g., NMs or UMs) or be at an increased risk of adverse effects (e.g., PMs). The FDA recommends atomoxetine doses up to 100 mg/day in adults or 1.2 mg/kg/day in children. This guideline proposes that CYP2D6 UMs (activity score >2 and 1–2% of US patients) and NMs (activity score 1–2 and 77–92% of US patients) may need higher than FDA recommended doses to achieve concentrations associated with clinical response, based on low atomoxetine peak concentrations (<200 ng/ml). It is estimated that up to 1/3 of US patients may be in this category of needing higher than recommended doses (30), but the exact prevalence needs to be established by future clinical studies. A potential risk of testing is the misinterpretation of genetic test results, as rare or novel variants are typically not interrogated. If an individual carries a rare variant, the actual phenotype may differ from the phenotype predicted by the genotypes included on a specific lab test. An individual's intrinsic CYP2D6 activity may also be impacted by other factors including epigenetics, diet, comorbidities, or co-medications. Any of these factors, including the co-medication with a CYP2D6 inhibitor, would be reflected through atomoxetine TDM. Although *CYP2D6* genotyping is usually reliable when performed in qualified laboratories, the possibility for error in genotyping, contamination, or mislabeling of the sample remains.

CAVEATS: APPROPRIATE USE AND/OR POTENTIAL MISUSE OF GENETIC TESTS

Rare *CYP2D6* variants may not be included in the genotype testing used by some laboratories, and patients with rare variants may be assigned a “wild-type” (*CYP2D6*1*) genotype by default. Thus, there is a small risk that an assigned “wild-type” allele could potentially harbor a no or decreased function variant. Furthermore, it is important that the genetic testing platform includes testing for gene copy number to identify *CYP2D6* ultrarapid metabolizers or gene deletions that may decrease *CYP2D6* AS. Caution should be used regarding molecular diagnostics of *CYP2D6* gene copy number variation since commercially available genotyping results may differ between diagnostic laboratories depending on assay design. Like all diagnostic tests, *CYP2D6* genotype is one of multiple pieces of information that clinicians should consider when making their therapeutic choice for each patient. Furthermore, there are several other factors that cause potential uncertainty in the genotyping results and phenotype predictions. These are discussed in detail in the Supplemental Material online.

In this guideline, we propose that exposure be assessed to guide subsequent dosing decisions when the desired clinical response has not been achieved, but we also recognize that this recommendation has limitations: available exposure-response data from clinical trials are derived from concentrations drawn 60–90 min after dosing; although this measure may not be the best predictor of response, the relationship between other exposure measures, such as trough concentration at steady state, steady state AUC, unbound atomoxetine concentrations, or total active compounds (unbound ATX + unbound 4-OH aglycone), has not been evaluated.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

We acknowledge the critical input of Dr. Mary V. Relling (St Jude Children’s Research Hospital) and the members of the Clinical Pharmacogenetics Implementation Consortium (CPIC).

FUNDING

This work was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264; U24HG010135–01) and PharmGKB (R24GM61374), PharmVar (R24GM123930). Atomoxetine studies conducted by the authors (JTB, AG and JSL) were supported by R01HD058556.

REFERENCES

- (1). PharmGKB. Gene Reference Materials for *CYP2D6*. <<https://www.pharmgkb.org/page/cyp2d6RefMaterials>>. Accessed September 16 2016.
- (2). CPIC. CPIC Guideline for Atomoxetine based on *CYP2D6* genotype. <<https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype>>.
- (3). Crews KR et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. *Clin Pharmacol Ther* 95, 376–82 (2014). [PubMed: 24458010]

- (4). Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ & Leeder JS The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. *Clin Pharmacol Ther* 83, 234–42 (2008). [PubMed: 17971818]
- (5). Crews KR et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. *Clin Pharmacol Ther* 91, 321–6 (2012). [PubMed: 22205192]
- (6). Hicks JK et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. *Clin Pharmacol Ther* 98, 127–34 (2015). [PubMed: 25974703]
- (7). Goetz MP et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. *Clin Pharmacol Ther* 103, 770–7 (2018). [PubMed: 29385237]
- (8). Hicks JK et al. Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. *Clin Pharmacol Ther* 102, 37–44 (2017). [PubMed: 27997040]
- (9). Bell GC et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. *Clin Pharmacol Ther* 102, 213–8 (2017). [PubMed: 28002639]
- (10). Danielson ML, Bitsko RH, Ghandour RM, Holbrook JR, Kogan MD & Blumberg SJ Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016. *J Clin Child Adolesc Psychol* 47, 199–212 (2018). [PubMed: 29363986]
- (11). Farid NA, Bergstrom RF, Ziege EA, Parli CJ & Lemberger L Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. *J Clin Pharmacol* 25, 296–301 (1985). [PubMed: 4008676]
- (12). Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J & Murphy D Trends of outpatient prescription drug utilization in US children, 2002–2010. *Pediatrics* 130, 23–31 (2012). [PubMed: 22711728]
- (13). Savill NC et al. The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research. *CNS Drugs* 29, 131–51 (2015). [PubMed: 25698145]
- (14). Sauer JM et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. *Drug Metab Dispos* 31, 98–107 (2003).
- (15). Brown JT, Abdel-Rahman SM, van Haandel L, Gaedigk A, Lin YS & Leeder JS Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. *Clin Pharmacol Ther* 99, 642–50 (2016). [PubMed: 26660002]
- (16). Michelson D, Read HA, Ruff DD, Witcher J, Zhang S & McCracken J CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. *J Am Acad Child Adolesc Psychiatry* 46, 242–51 (2007). [PubMed: 17242628]
- (17). FDA. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. <<https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table2-1>> (2017).
- (18). Ring BJ, Gillespie JS, Eckstein JA & Wrighton SA Identification of the human cytochromes P450 responsible for atomoxetine metabolism. *Drug Metab Dispos* 30, 319–23 (2002). [PubMed: 11854152]
- (19). Trzepacz PT, Williams DW, Feldman PD, Wrishko RE, Witcher JW & Buitelaar JK CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. *Eur Neuropsychopharmacol* 18, 79–86 (2008). [PubMed: 17698328]
- (20). Dinh JC, Pearce RE, Van Haandel L, Gaedigk A & Leeder JS Characterization of atomoxetine biotransformation and implications for development of PBPK models for dose individualization in children. *Drug Metab Dispos* 44, 1070–9 (2016). [PubMed: 27052878]
- (21). Monroe WM Fifty years of change. *Va Med* 116, 281–2 (1989). [PubMed: 2763638]
- (22). Byeon JY et al. Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites. *Arch Pharm Res* 38, 2083–91 (2015). [PubMed: 26254792]

- (23). Matsui A et al. Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men. *J Clin Pharmacol* 52, 388–403 (2012). [PubMed: 21543662]
- (24). Cui YM et al. Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. *Br J Clin Pharmacol* 64, 445–9 (2007). [PubMed: 17610534]
- (25). Fijal BA et al. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. *J Clin Pharmacol* 55, 1167–74 (2015). [PubMed: 25919121]
- (26). Newcorn JH, Sutton VK, Weiss MD & Sumner CR Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. *J Am Acad Child Adolesc Psychiatry* 48, 511–8 (2009). [PubMed: 19318988]
- (27). Schoretsanitis G et al. TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians<sup/>. *World J Biol Psychiatry* 19, 162–74 (2018). [PubMed: 29493375]
- (28). Hiemke C et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. *Pharmacopsychiatry* 51, e1 (2018).
- (29). Hazell P et al. Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. *Atten Defic Hyperact Disord* 1, 201–10 (2009). [PubMed: 20234828]
- (30). de Leon J Translating pharmacogenetics to clinical practice: Do cytochrome P450 2D6 ultrarapid metabolizers need higher atomoxetine doses? *J Am Acad Child Adolesc Psychiatry* 54, 532–4 (2015). [PubMed: 26088654]
- (31). Ramoz N et al. A haplotype of the norepinephrine transporter (Net) gene *Slc6a2* is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). *Neuropsychopharmacology* 34, 2135–42 (2009). [PubMed: 19387424]
- (32). Todor I et al. Evaluation of a potential metabolism-mediated drug-drug interaction between atomoxetine and bupropion in healthy volunteers. *J Pharm Pharm Sci* 19, 198–207 (2016). [PubMed: 27518170]
- (33). Paulzen M, Clement HW & Grunder G Enhancement of atomoxetine serum levels by co-administration of paroxetine. *Int JNeuropsychopharmacol* 11, 289–91 (2008). [PubMed: 18215333]
- (34). Kratochvil CJ et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. *J Am Acad Child Adolesc Psychiatry* 44, 915–24 (2005). [PubMed: 16113620]
- (35). Spina E, Pisani F & de Leon J Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. *Pharmacol Res* 106, 72–86 (2016). [PubMed: 26896788]
- (36). Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T & Leeder JS Prediction of CYP2D6 phenotype from genotype across world populations. *Genet Med*, (2016).
- (37). CPIC. CPIC Guideline for Tamoxifen based on CYP2D6 genotype. <<https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/>>.
- (38). Whirl-Carrillo M et al. Pharmacogenomics knowledge for personalized medicine. *Clin Pharmacol Ther* 92, 414–7 (2012). [PubMed: 22992668]




Figure 1. Atomoxetine Pathway, Pharmacokinetics.

Data observed from Reference (38), M. Whirl-Carrillo, E.M. McDonagh, J. M. Hebert, L. Gong, K. Sangkuhl, C.F. Thorn, R.B. Altman and T.E. Klein. "Pharmacogenomics Knowledge for Personalized Medicine" *Clinical Pharmacology & Therapeutics* (2012) 92(4): 414–417.

Image reproduced and is licensed under CC BY-SA 4.0 from PharmGKB.

TABLE 1.
ASSIGNMENT OF LIKELY CYP2D6 PHENOTYPES BASED ON DIPTOTYPES

Likely phenotype ^b	Activity Score	Genotypes ^d	Examples of CYP2D6 diplotypes
CYP2D6 ultrarapid metabolizer	>2	An individual carrying duplications of functional alleles	*1/*1xN, *1/*2xN, *2/*2xN ^c
CYP2D6 normal metabolizer	1.5 –2.0	An individual carrying two normal function alleles or one normal function and one decreased function allele	*1/*1, *1/*2, *1/*9, *1/*41, *2/*2
CYP2D6 normal metabolizer or intermediate metabolizer (controversy remains) ^d	1.0	An individual carrying two decreased function alleles or one normal function and one no function allele. <i>An activity score (AS) of 1.0 is associated with decreased atomoxetine metabolism compared to those with an AS of 1.5 or 2.</i>	*1/*4, *1/*5, *41/*41, *10/*10
CYP2D6 intermediate metabolizer	0.5	An individual carrying one decreased function and one no function allele	*4/*10, *4/*41, *7/*9
CYP2D6 poor metabolizer	0	An individual carrying only no functional alleles	*3/*4, *4/*4, *5/*5, *5/*6

^a Assignment of allele function and citations for allele function can be found <https://www.pharmgkb.org/page/cyp2d6RefMaterials> (CYP2D6 Allele Definition Table and CYP2D6 Allele Functionality Table (1, 2)). For a complete list of CYP2D6 diplotypes and resulting phenotypes, see the CYP2D6 Genotype to Phenotype Table (1, 2). Note that genotypes with an activity score of 1 are classified as NMs in the online CYP2D6 genotype to phenotype table.

^b See the CYP2D6 Frequency Table for race-specific allele and phenotype frequencies or see Gaedigk et al (1, 2, 36).

^c Where xN represents the number of CYP2D6 gene copies. For individuals with CYP2D6 duplications or multiplications, see supplemental data for additional information on how to translate diplotypes into phenotypes.

^d Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories. A group of CYP2D6 experts are currently working to standardize the CYP2D6 genotype to phenotype translation system. CPIC will update the CPIC website accordingly (CYP2D6 Genotype to Phenotype Table (1, 37)).

TABLE 2.
DOSING RECOMMENDATIONS FOR ATOMOXETINE BASED ON CYP2D6 GENOTYPE FOR CHILDREN

Phenotype	Activity score	Implication	Therapeutic Recommendation	Classification of Recommendation ^a
CYP2D6 ultrarapid metabolizer	>2	Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. ^{b,c}	Moderate
CYP2D6 normal metabolizer	1.5–2.0	Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.	Initiate with a dose of 0.5 mg/kg and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. ^{b,c}	Moderate
CYP2D6 normal metabolizer or intermediate metabolizer (controversy remains) ^d	1.0 (no *10 allele present)	Possibly higher atomoxetine concentrations as compared to normal metabolizers but questionable clinical significance. Normal metabolizers with AS of 1 may be at an increased risk of increased discontinuation as compared to poor metabolizers.	Initiate with a dose of 0.5 mg/kg and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. ^{b,c}	Moderate
CYP2D6 normal metabolizer or intermediate metabolizer (controversy remains) ^d	1.0 (*10 present)	Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Individuals with activity score of 1.0 with CYP2D6*10 may be at an increased risk of increased discontinuation as compared to poor metabolizers.	Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2–4 h after dosing. If response is inadequate and concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. ^{b,c} If unacceptable side effects are present at any time, consider a reduction in dose.	Moderate
CYP2D6 intermediate metabolizer	0.5	Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Intermediate metabolizers may be at an increased risk of discontinuation as compared to poor metabolizers.	Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2–4 h after dosing. If response is inadequate and concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. ^{b,c} If unacceptable side effects are present at any time, consider a reduction in dose.	Moderate
CYP2D6 poor metabolizer	0	Significantly decreased metabolism of atomoxetine may result in higher concentrations as compared to non-poor metabolizers. This may	Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 4 h after dosing. If response is inadequate and concentration is <200 ng/ml, consider a proportional dose increase to	Strong

Phenotype	Activity score	Implication	Therapeutic Recommendation	Classification of Recommendation ^a
		increase the occurrence of side effects, but also a greater improvement of ADHD symptoms as compared to non-poor metabolizers in those who tolerate treatment. Poor metabolizer status is associated with lower final dose requirements as compared to non-poor metabolizers.	achieve a concentration to approach 400 ng/ml. ^{b,c} If unacceptable side effects are present at any time, consider a reduction in dose.	

^aRating scheme described in the Supplement.

^bTherapeutic range of 200 to 1000 ng/ml has been proposed (27).

^cLimited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in PMs compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-RS, is observed at peak concentrations greater than 400 ng/ml.

^dCPIC has general classified patients with activity score of 1 as “normal metabolizer.” However, in the case of atomoxetine, prescribing recommendations for those with an AS of 1.0 are allele-dependent, based on the presence of the *CYP2D6*10* allele.

DOSING RECOMMENDATIONS FOR ATOMOXETINE BASED ON CYP2D6 GENOTYPE FOR ADULTS

TABLE 3.

Phenotype	Activity score	Implication	Therapeutic Recommendation	Classification of Recommendation ^a
CYP2D6 ultrarapid metabolizer	>2	Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. ^{b,c} Dosages greater than 100 mg/day may be needed to achieve target concentrations. ^d	Moderate
CYP2D6 normal metabolizer	1.5–2.0	Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. ^{b,c} Dosages greater than 100 mg/day may be needed to achieve target concentrations. ^d	Moderate
CYP2D6 Normal metabolizer or Intermediate metabolizer (controversy remains) ^e	1.0 (*10 allele not present)	Possibly higher atomoxetine concentrations as compared to normal metabolizers but questionable clinical significance. Normal metabolizers may be at an increased risk of increased discontinuation as compared to poor metabolizers.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. ^{b,c} Dosages greater than 100 mg/day may be needed to achieve target concentrations. ^d	Moderate
CYP2D6 Normal metabolizer or Intermediate metabolizer (controversy remains) ^e	1.0 (*10 allele present)	Decreased metabolism of atomoxetine higher atomoxetine concentrations as compared to normal metabolizers. Individuals with activity score of 1.0 with CYP2D6*10 may be at an increased risk of increased discontinuation as compared to poor metabolizers.	Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2–4 h after dosing. If concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. ^{b,c} If unacceptable side effects are present at any time, consider a reduction in dose.	Moderate
CYP2D6 intermediate metabolizer	0.5	Decreased metabolism of atomoxetine higher atomoxetine concentrations as compared to normal metabolizers. Intermediate metabolizers may be at an increased risk of	Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2–4 h after dosing. If concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. ^{b,c} If unacceptable side effects are present at any time, consider a reduction in dose.	Moderate

Phenotype	Activity score	Implication	Therapeutic Recommendation	Classification of Recommendation ^a
CYP2D6 poor metabolizer	0	discontinuation as compared to poor metabolizers. Significantly decreased metabolism of atomoxetine may result in higher	Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2–4 h after dosing. If concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. ^{b,c} If unacceptable side effects are present at any time, consider a reduction in dose.	Moderate

^aRating scheme described in the Supplement.

^bTherapeutic range of 200 to 1000 ng/ml has been proposed (27).

^cLimited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in PMs compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-RS, is observed at peak concentrations greater than 400 ng/ml.

^dDoses above 120 mg/day have not been evaluated.

^eCPIC has general classified patients with activity score of 1 as “normal metabolizer.” However, in the case of atomoxetine, prescribing recommendations for those with an AS of 1.0 are allele-dependent, based on the presence of the *CYP2D6*10* allele.